Paratek Pharmaceuticals Reports Topline Results from P-IIb Study of Nuzyra (Omadacycline) for Nontuberculous Mycobacterial Abscessus Pulmonary Disease
Shots:
- The P-IIb trial assessed Nuzyra (oral) vs PBO to treat Mycobacterium abscessus pulmonary disease in patients (n=66) for 84 days, followed by a safety follow-up duration of 30 days
- A trend favoring the 1 & 2EPs. was seen, with 1EP assessed via NTM Symptom Assessment Scale at D84 in two methods, improvement in at least 50% of baseline symptoms (Evaluation 1) & the same improvement without worsening of any baseline symptoms (Evaluation 2)
- Study depicted response rates of 34.1% vs 20% (evaluation 1) & 34.1% vs 12% (evaluation 2) with better QOL-Bronchiectasis scores, 56.4% vs 29.2% rates of negative sputum cultures for MABc & 76.5% vs 45.8% reductions in sputum culture scores at D84. Full results will be provided later
Ref: Paratek | Image: Paratek
Related News:- Cytoki Pharma Reports the First Patient Dosing with CK-0045 in the P-II Trial for Treating Obesity and Type 2 Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
